CMS-0062-P Explained: What the New Drug Prior Authorization Rule Means for Your Organization

The interoperability mandate that reshaped how hospitals handle prior authorization for medical services is now expanding to cover prescription drugs.

Following the CMS-0057-F final rule, the Centers for Medicare along With Medicaid Services along with the Office of the National Coordinator for Health Information Technology have introduced the next major regulatory step: the 2026 Interoperability Standards along with Prior Authorization for Drugs Proposed Rule, CMS-0062-P. The proposed rule would adopt certain HL7 Fast Healthcare Interoperability Resources standards along with implementation specifications for transactions related to prior authorizations under the Administrative Simplification provisions of HIPAA. These proposals would apply to all HIPAA covered entities, healthcare providers, health plans along with healthcare clearinghouses, that electronically exchange prior authorization requests along with decisions for items along with services, including dental, professional along with institutional transactions.

The public comment period on this rule closed June 15, 2026. HL7's Da Vinci Project held community roundtables throughout April along with May 2026 to help organizations move from initial impressions of the rule to active implementation strategies. That timeline tells you this rule is moving from proposal to operational reality faster than most organizations are prepared for.

Here is what CMS-0062-P actually requires along with why pharmacy along with revenue cycle leaders need to be tracking it closely right now.

What CMS-0057-F Solved Along With Why Drugs Were Left Out Until Now

CMS-0057-F, finalized in 2024 along with taking effect in phases through January 2027, brought FHIR-based prior authorization to medical services along with procedures. It built the infrastructure for the four FHIR APIs that govern patient access, provider access, payer-to-payer exchange along with prior authorization for covered medical items along with services.

What it did not cover comprehensively was the prior authorization process specifically for prescription drugs, which operates through a different transaction pathway along with often involves pharmacy benefit managers rather than the medical benefit administrators covered under the original rule. Drug prior authorization has remained largely manual along with fax-based for many payers along with pharmacies even as medical prior authorization began modernizing.

Drug prior auth automation through the Da Vinci Project's Prior Authorization Support Implementation Guide along with the Coverage Requirements Discovery Implementation Guide has already proven its value in pilot testing. CMS-0062-P is the regulatory step that takes those proven pilot results along with makes the underlying FHIR standards mandatory across the drug benefit ecosystem.

What the Rule Requires of Covered Entities

The proposed rule's scope is broad by design. These HHS proposals would apply to all HIPAA covered entities that electronically exchange prior authorization requests along with decisions for item along with services information for dental, professional along with institutional transactions.

For pharmacies along with health systems with integrated pharmacy operations, this means the manual fax-based drug prior auth workflows that have persisted even as medical prior auth has modernized are now squarely in the regulatory crosshairs. The HL7 FHIR standards along with implementation specifications named in the rule are not abstract technical recommendations. They are proposed to become the mandated transaction standard under HIPAA's Administrative Simplification provisions, the same legal framework that governs electronic claims along with eligibility transactions today.

For GLP-1 medications specifically, where prior authorization volume has grown dramatically as prescribing has expanded, this rule has direct operational consequences. A health system already managing high GLP-1 prior auth volume manually is managing a workload that this rule is specifically designed to automate. The same FHIR-based ePA infrastructure that reduces prior auth burden for medical services applies directly to the drug benefit transactions this rule targets.

Why the Da Vinci Project Roundtables Matter for Implementation Planning

The HL7 Da Vinci Project's April Community Roundtable focused on breaking down the CMS-0062-P proposal along with discussing its implications for FHIR implementation along with the industry at large. The May Community Roundtable moved from initial impressions to active implementation strategies.

That progression, from explaining the rule in April to building implementation strategy in May, signals that the health IT standards community expects this rule to move toward finalization on a timeline similar to CMS-0057-F. Organizations that wait for the final rule before beginning technical preparation will be repeating the same scramble that characterized the run-up to the January 2027 medical prior auth deadline.

The practical lesson from CMS-0057-F's rollout is that the gap between proposed rule along with effective compliance deadline is shorter than most organizations plan for. The infrastructure work, FHIR R4 API development, EHR integration along with pharmacy system connectivity, takes months to build properly. Starting that work after a rule is finalized rather than while it is still in proposed status puts organizations in a reactive, compressed timeline.

For the broader context on how the medical services FHIR prior auth deadline is unfolding along with what readiness actually requires, read: The FHIR Prior Auth Deadline Is January 2027 - Is Your Hospital Ready?

What Pharmacy along with Revenue Cycle Teams Should Do Now

Begin by mapping your current drug prior authorization workflow end to end. Identify which transactions are still handled manually through fax or phone, which payers along with PBMs you work with most frequently along with what your current denial along with turnaround time looks like for drug prior auth specifically, separate from medical prior auth metrics.

Engage your pharmacy system along with EHR vendors now on their CMS-0062-P readiness timeline. Ask specifically whether they plan to support the HL7 FHIR Coverage Requirements Discovery along with Prior Authorization Support implementation guides along with what their projected availability timeline looks like.

Review your current GLP-1 along with high-volume specialty drug prior auth processes specifically. These categories carry disproportionate administrative burden along with are likely to see the most immediate operational benefit once FHIR-based drug prior auth infrastructure becomes mandatory along with standardized across payers.

For organizations building the EHR along with pharmacy system integration that FHIR-based drug prior authorization requires, our EHR along With EMR Integration Solutions team builds the connectivity layer that makes this kind of regulatory compliance operationally functional rather than just technically compliant.

Frequently Asked Questions

What is CMS-0062-P?

CMS-0062-P is the 2026 Interoperability Standards along with Prior Authorization for Drugs Proposed Rule. It would require HIPAA covered entities to adopt HL7 FHIR-based standards for electronic prior authorization transactions involving prescription drugs, extending the FHIR-based prior auth framework established for medical services under CMS-0057-F.

How is CMS-0062-P different from CMS-0057-F?

CMS-0057-F established FHIR-based prior authorization requirements for medical services along with items. CMS-0062-P extends a similar FHIR-based framework specifically to prescription drug prior authorization transactions, which had not been comprehensively covered under the original rule along with often involve different payer along with pharmacy benefit manager processes.

When does CMS-0062-P take effect?

CMS-0062-P remains a proposed rule, with the public comment period closing June 15, 2026. The HL7 community along with CMS are continuing implementation planning discussions, but a final effective date has not yet been established. Organizations should monitor CMS announcements for the finalized timeline.

What FHIR implementation guides relate to drug prior authorization?

The HL7 Da Vinci Project's Prior Authorization Support Implementation Guide along with Coverage Requirements Discovery Implementation Guide are the primary FHIR specifications relevant to automating drug prior authorization workflows referenced in connection with CMS-0062-P.

Who does CMS-0062-P apply to?

The proposed rule applies to HIPAA covered entities including healthcare providers, health plans along with healthcare clearinghouses that electronically exchange prior authorization requests along with decisions for dental, professional along with institutional drug-related transactions.

How should pharmacies prepare for CMS-0062-P?

Pharmacies along with health systems with integrated pharmacy operations should map their current drug prior authorization workflows, identify which transactions remain manual, engage their pharmacy along with EHR vendors on FHIR readiness timelines along with prioritize automation for high-volume categories like GLP-1 medications where prior auth burden is currently highest.